1.
World Health Organization. WHO Global Tuberculosis Report Executive Summary 2018 [Internet].
2018. Available from: http://www.who.int/tb/publications/global_report/tb18_ExecSum_web_4Oct18.pdf
3.
Kisambu J, Nuwaha F, Sekandi JN. Adherence to treatment and supervision for tuberculosis
in a DOTS programme among pastoralists in Uganda. Int J Tuberc Lung Dis. 2014;18(7):799–803.
4.
Kaona FAD, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment
adherence and knowledge of TB transmission among patients on TB treatment. BMC Public
Health. 2004;4:1–8.
5.
Kebede A, Wabe NT. Medication adherence and its determinants among patients on concomitant
tuberculosis and antiretroviral therapy in south west Ethiopia. N Am J Med Sci. 2012;4(2):67–71.
6.
Woimo TT, Yimer WK, Bati T, Gesesew HA. The prevalence and factors associated for
anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in
public health care facilities in South Ethiopia: a cross-sectional study. BMC Public
Health. 2017;17(1):1–10.
7.
van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring
of treatment adherence and validation of alternative adherence measures in tuberculosis
patients: A pilot study. Bull World Health Organ. 2011;89(9):632–9.
8.
Kidenya BR, Mshana SE, Gerwing-Adima L, Kidola J, Kasang C. Drug adherence and efficacy
of smear microscopy in the diagnosis of pulmonary tuberculosis after 2 months of medication
in North-western Tanzania. Int J Infect Dis [Internet]. 2017;63:43–7. Available from:
http://dx.doi.org/10.1016/j.ijid.2017.07.025
10.
Van Den Boogaard J, Lyimo R, Irongo CF, Boeree MJ, Schaalma H, Aarnoutse RE, et al.
Community vs. facility-based directly observed treatment for tuberculosis in Tanzania’s
Kilimanjaro Region. Int J Tuberc Lung Dis. 2009;13(12):1524–9.
11.
Van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response
relationship in tuberculosis treatment: Why are we still in the dark and how can we
get out? Trop Med Int Heal. 2011;16(6):693–8.
12.
Adane AA, Alene KA, Koye DN, Zeleke BM. Non-adherence to anti-tuberculosis treatment
and determinant factors among patients with tuberculosis in northwest Ethiopia. PLoS
One. 2013;8(11).
13.
Habteyes Hailu Tola1, 2*, Gholamreza Garmaroudi1, Davoud Shojaeizadeh1, Azar Tol1,
Mir Saeed Yekaninejad3, Luche Tadesse Ejeta1, Abebaw Kebede2 DK. The Effect of Psychosocial
Factors and Patient s ’ Perception of Tuberculosis Treatment Non-Adherence in Addis
Ababa , Ethiopia. Ethiop J Heal Sci. 2017;27(5):447–58.
15.
Méda ZC, Lin YT, Sombié I, Maré D, Morisky DE, Chen YMA. Medication-adherence predictors
among patients with tuberculosis or human immunodeficiency virus infection in Burkina
Faso. J Microbiol Immunol Infect. 2014;47(3):222–32.
16.
Ali AOA, Prins MH. Patient non adherence to tuberculosis treatment in Sudan: Socio
demographic factors influencing non adherence to tuberculosis therapy in Khartoum
State. Pan Afr Med J. 2016;25:1–11.
17.
Dick J LC. Shared vision - a health education project designed to enhance adherence
to anti-tuberculosis treatment. Int J Tuberc Lung Dis. 1997;1(2):181–6.
18.
Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of
the impact of counselling on treatment adherence of tuberculosis patients in Sialkot,
Pakistan. Int J Tuberc Lung Dis. 1999;3(12):1073–80.
19.
Nhavoto JA, Gronlun A, Klein GO. Mobile health treatment support intervention for
HIV and tuberculosis in Mozambique : Perspectives of patients and healthcare workers.
PLoS One. 2017;1–13.
20.
Bediang G, Stoll B, Elia N, Abena JL, Nolna D, Chastonay P, et al. SMS reminders to
improve the tuberculosis cure rate in developing countries (TB-SMS Cameroon): A protocol
of a randomised control study. Trials. 2014;15(1):1–9.
21.
Mesfin MM, Newell JN, Walley JD, Gessessew A, Tesfaye T, Lemma F, et al. Quality of
tuberculosis care and its association with patient adherence to treatment in eight
Ethiopian districts. Health Policy Plan. 2009;24(6):457–66.
22.
Jaiswal A, Singh V, Ogden JA, Porter JDH, Sharma PP, Sarin R, et al. Adherence to
tuberculosis treatment: Lessons from the urban setting of Delhi, India. Trop Med Int
Heal. 2003;8(7):625–33.
23.
Sagbakken M, Frich JC, Bjune G. Barriers and enablers in the management of tuberculosis
treatment in Addis Ababa, Ethiopia: A qualitative study. BMC Public Health. 2008;8:1–11.
24.
Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am
J Heal Promot. 1997;12(1):38–48.
25.
Willey C(1), Redding C, Stafford J, Garfield F, Geletko S, Flanigan T M, K, Mitty
J CJ. Stages of change for adherence with medication regimens for chronic disease:
development and validation of a measure. Clin Ther. 2000;22(7):858–71.
26.
Kavookjian J, Berger BA, Grimley DM, Villaume WA, Anderson HM, Barker KN. Patient
decision making: Strategies for diabetes diet adherence intervention. Res Soc Adm
Pharm. 2005;1(3):389–407.
27.
Liu Q, Abba K, Alejandria MM, Sinclair D, Balanag VM, Lansang MAD. Reminder systems
to improve patient adherence to tuberculosis clinic appointments for diagnosis and
treatment. Cochrane Database Syst Rev. 2014;2014(11).
28.
Marcolino MS, Oliveira JAQ, D’Agostino M, Ribeiro AL, Alkmim MBM, Novillo-Ortiz D.
The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. JMIR
mHealth uHealth [Internet]. 2018;6(1):e23. Available from: http://mhealth.jmir.org/2018/1/e23/
33.
Lei X, Liu Q, Wang H, Tang X, Li L, Wang Y. Is the short messaging service feasible
to improve adherence to tuberculosis care? A cross-sectional study. Trans R Soc Trop
Med Hyg. 2013;107(10):666–8.
35.
Hermans SM, Elbireer S, Tibakabikoba H, Hoefman BJ, Manabe YC. Text messaging to decrease
tuberculosis treatment attrition in TB-HIV coinfection in Uganda. Patient Prefer Adherence.
2017;11:1479–87.
36.
Mohammed S, Glennerster R, Khan AJ. Impact of a Daily SMS Medication Reminder System
on Tuberculosis Treatment Outcomes : A Randomized Controlled Trial. 2016;1–14.
37.
Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of Electronic
Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised
Trial. PLoS Med. 2015;12(9):1–18.
38.
Abdulrahman SA, Rampal L, Ibrahim F, Radhakrishnan AP, Shahar HK, Othman N. Mobile
phone reminders and peer counseling improve adherence and treatment outcomes of patients
on ART in Malaysia: A randomized clinical trial. PLoS One. 2017;12(5):1–16.
39.
Fang X-H, Guan S-Y, Tang L, Tao F-B, Zou Z, Wang J-X, et al. Effect of Short Message
Service on Management of Pulmonary Tuberculosis Patients in Anhui Province, China:
A Prospective, Randomized, Controlled Study. Med Sci Monit [Internet]. 2017;23:2465–9.
Available from: http://www.medscimonit.com/abstract/index/idArt/904957
40.
Subbaraman R, Mayer K, Muslimenta A, Thomas B. Digital adherence technologies for
the treatment of tuberculosis: landscape and research priorities. BMJ Glob Heal. 2018;3:1–16.
42.
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico KR, Friedland G, et al. Pilot evaluation
of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral
therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
BMC Infect Dis. 2018;18(1):1–9.
43.
Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse
RE, et al. Feasibility of Real Time Medication Monitoring Among HIV Infected and TB
Patients in a Resource-Limited Setting. AIDS Behav. 2016;20(5):1097–107.
44.
Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a medication
event reminder monitor system (MERM) by providers and patients to improve adherence
in the management of tuberculosis. Int J Environ Res Public Health. 2017;14(10):1–11.
45.
Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence
monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.
46.
DeSilva MB, Gifford AL, Xu K, Li Z, Feng C, Brooks M, et al. Feasibility and acceptability
of a real-time adherence device among HIV-positive IDU patients in China. (Special
Issue: Using mobile health technology to improve HIV care for persons living with
HIV and substance abuse.). AIDS Res Treat. 2013;957862(16).
47.
Sabin LL, DeSilva MB, Gill CJ, Li Z. Improving Adherence to Antiretroviral Therapy
with Triggered Real Time Text Message Reminders: the China through Technology Study
(CATS). J Acquir Immune Defic Syndr. 2015;69(5):551–559.
48.
Stop TB Partnership. TB Medication Adherence & Treatment Outcomes. Vol. 3. 2017.
49.
National Tuberculosis and Leprosy Programme. Tuberculosis data from Kilimanjaro, Tanzania.
2017.
50.
World Health Organization. United Republic of Tanzania: Tuberculosis profile. 2016;
Available from: https://extranet.who.int/sree/Reports?op=Replet&name=/WHO_HQ_Reports/G2/PROD/EXT/TBCountryProfile&ISO2=TZ&outtype=PDF
51.
Van Rie A, Sengupta S, Pungrassami P, Balthip Q, Choonuan S, Kasetjaroen Y, et al.
Measuring stigma associated with tuberculosis and HIV/AIDS in southern Thailand: Exploratory
and confirmatory factor analyses of two new scales. Trop Med Int Heal. 2008;13(1):21–30.
52.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
data capture (REDCap)--a metadata-driven methodology and workflow process for providing
translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
53.
Hassard S, Ronald A, Angella K. Patient attitudes towards community-based tuberculosis
DOT and adherence to treatment in an urban setting; Kampala, Uganda. Pan Afr Med J.
2017;27:1–6.
54.
Kipp AM, Pungrassami P, Stewart PW, Chongsuvivatwong V, Strauss RP, Van Rie A. Study
of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using
validated stigma scales. Int J Tuberc Lung Dis. 2011;15(11):1540–5.
55.
Chowdhury MRK, Rahman MS, Mondal MNI, Sayem A, Billah B. Social impact of stigma regarding
tuberculosis hindering adherence to treatment: A cross sectional study involving tuberculosis
patients in Rajshahi City, Bangladesh. Jpn J Infect Dis. 2015;68(6):461–6.
56.
Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection
of the time course of drug concentration in plasma during a 1-year period from electronically
compiled dosing-time data used as input to individually parameterized pharmacokinetic
models. J Clin Pharmacol. 2005;45(4):461–7.